Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

ABIVAX Société Anonyme

Healthcare US AAVXF

89.3USD
18.04(25.32%)

Last update at 2026-06-03T19:09:00Z

Day Range

86.2689.30
LowHigh

52 Week Range

5.81133.40
LowHigh

Fundamentals

  • Previous Close 71.26
  • Market Cap9781.09M
  • Volume200
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-244.98301M
  • Revenue TTM4.57M
  • Revenue Per Share TTM0.07
  • Gross Profit TTM 4.57M
  • Diluted EPS TTM-5.69

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -333.19016M -176.24200M -152.23300M -74.32300M -45.56100M
Minority interest - - - - -
Net income -335.97612M -176.24200M -147.74000M -69.84600M -41.35700M
Selling general administrative 72.86M 32.95M 22.39M 49.61M 44.97M
Selling and marketing expenses - 5.95M 6.43M - -
Gross profit -1.07160M 10.79M 4.49M -0.11000M 0.04M
Reconciled depreciation 1.07M 1.10M 0.71M 0.31M 0.16M
Ebit -250.53113M -172.98300M -133.91400M -56.75700M -42.53500M
Ebitda -249.45953M -171.88300M -133.20700M -56.44800M -42.37900M
Depreciation and amortization 1.07M 1.10M 0.71M 0.31M 0.16M
Non operating income net other - - - - -
Operating income -250.53113M -172.98400M -127.37600M -56.64500M -42.56000M
Other operating expenses 250.53M 183.78M 131.87M 56.65M 42.60M
Interest expense 28.50M 4.18M 13.83M 3.70M 3.15M
Tax provision 5.85M 0.00000M 0.00000M -4.47600M -4.20400M
Interest income 5.75M 8.96M 2.77M 0.13M 0.08M
Net interest income -52.48600M -4.56400M -12.74900M -3.80600M -3.12600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.79M - -4.49300M -4.47600M -4.20400M
Total revenue 0.00000M 10.79M 4.62M 0.00000M 0.04M
Total operating expenses 249.46M 183.78M 127.38M 56.54M 42.60M
Cost of revenue 1.07M - 0.13M 0.11M 0.00000M
Total other income expense net -82.65903M -3.25800M -24.85700M -17.67800M -3.00100M
Discontinued operations - - - - -
Net income from continuing ops -336.10200M -176.24200M -147.74000M -69.84700M -41.35700M
Net income applicable to common shares - - - -60.74000M -41.35700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 584.12M 205.23M 327.06M 73.35M 110.36M
Intangible assets 6.60M 6.61M 6.60M -13.13800M -0.64700M
Earning assets - - - - -
Other current assets 10.36M 10.79M 24.98M - 5.11M
Total liab 129.09M 164.64M 131.05M 64.65M 74.75M
Total stockholder equity 455.03M 40.58M 196.01M 8.70M 35.61M
Deferred long term liab - - - - -
Other current liab 61.70M 0.53M 9.78M 3.08M 2.65M
Common stock 0.78M 0.63M 0.63M 0.22M 0.17M
Capital stock 0.79M 0.63M 0.63M 0.22M 0.17M
Retained earnings -738.20541M -438.87900M -282.94900M -148.75400M -78.90800M
Other liab - - - 1.22M 0.10M
Good will 18.41M 18.42M 18.42M 36.66M 32.74M
Other assets - -0.00100M - 12.74M 2.96M
Cash 516.49M 144.22M 251.94M 26.94M 60.70M
Cash and equivalents - - - - -
Total current liabilities 63.00M 92.83M 70.04M 28.04M 21.21M
Current deferred revenue - - 0.05M - -
Net debt -484.41050M -46.86000M -196.47800M 19.12M -7.24300M
Short term debt 1.30M 43.77M 10.61M 9.49M 0.00700M
Short long term debt - 42.84M 10.23M 9.49M 0.00700M
Short long term debt total 32.08M 97.36M 55.46M 46.07M 53.45M
Other stockholder equity 1190.15M 478.90M 478.22M 157.23M 114.35M
Property plant equipment - - - 1.59M 0.09M
Total current assets 551.04M 170.67M 285.97M 48.19M 75.21M
Long term investments 0.00000M 0.13M 0.12M - -
Net tangible assets - - - -17.83700M 3.51M
Short term investments 13.69M 0.14M 9.05M 0.00600M 0.00600M
Net receivables 10.49M 15.66M 19.10M 8.32M 4.70M
Long term debt - 52.16M 44.70M 36.58M 53.45M
Inventory - - 0.00000M - 4.00M
Accounts payable 37.55M 43.82M 47.22M 15.47M 18.55M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.31M -0.07500M 0.11M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.98M 6.74M 15.06M 1.24M 2.75M
Deferred long term asset charges - - - - -
Non current assets total 33.08M 34.56M 41.09M 25.16M 35.15M
Capital lease obligations 1.86M 2.36M 0.54M - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 15.76M -8.09500M -0.51300M -1.45600M
Change to liabilities - - - -2.41400M 1.10M
Total cashflows from investing activities -13.71786M 15.76M -8.09500M -12.02600M -1.45600M
Net borrowings -59.53300M 37.49M 15.24M -9.80100M 13.05M
Total cash from financing activities 553.59M 28.21M 335.29M 48.03M 78.51M
Change to operating activities - - - - 2.59M
Net income -335.97612M -176.24200M -147.74000M -37.63300M -42.56000M
Change in cash 389.42M -107.72100M 224.99M 19.53M 31.40M
Begin period cash flow 127.07M 251.94M 26.95M 9.77M 29.30M
End period cash flow 516.49M 144.22M 251.94M 29.30M 60.70M
Total cash from operating activities -162.02829M -154.07200M -97.13000M -27.98900M -45.65700M
Issuance of capital stock 648.12M 0.43M 353.39M 28.59M 65.47M
Depreciation 1.07M 1.10M 0.71M 0.31M 0.16M
Other cashflows from investing activities 0.07M 16.40M 0.78M -8.79000M -0.12600M
Dividends paid 0.00000M 0.00000M 0.00000M - -
Change to inventory - - - - -
Change to account receivables 7.04M 4.59M -14.23100M 0.31M -4.00000M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.61077M -9.71300M -33.33600M 22.80M 25.00M
Change to netincome - - - 8.32M -2.94300M
Capital expenditures 0.14M 0.64M 0.27M 0.04M 1.64M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.65M 1.42M 21.27M 7.22M -1.41400M
Stock based compensation 35.40M 20.22M 8.18M 0.15M -
Other non cash items 169.23M -0.57700M 20.46M 1.96M -1.83900M
Free cash flow -162.17024M -154.71500M -97.39500M -28.03200M -47.29900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AAVXF
ABIVAX Société Anonyme		 18.04 25.32% 89.30 - 0.94 2140.28 17.11 157.63 -7.5116
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme

7-11 Boulevard Haussmann, Paris, France, 75009

Key Executives

Name Title Year Born
Prof. Hartmut J. Ehrlich Chief Exec. Officer NA
Dr. Philippe Pouletty M.D., Ph.D. Founder & Director 1958
Mr. Didier Blondel EVP, CFO & Board Sec. NA
Ms. Raquel Lizarraga Investor Relations Mang. NA
Ms. Regina Jehle VP Communications NA
Anne Pascard HR Mang. NA
Mr. Pierre Courteille M.B.A. Chief Commercial Officer & VP of Bus. Devel. NA
Dr. Alexandra Pearce VP of Regulatory Affairs, Quality & Pharmaco-Vigilance NA
Mr. Paul Gineste VP Clinical Operations NA
Mr. Alain Chevallier Sr. Advisor 1953

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.